Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
MarketWatch on MSN40m
Fortinet’s stock falls 9% after cybersecurity company’s quarterly billings dropShares of Fortinet Inc. fell 9% in the extended session Thursday after the cybersecurity company reported a ...
Jeffrey Rittichier, EMCORE’s President and CEO stated, “We are very pleased to announce the execution of a transaction to transfer substantially all assets related to our Chips business and InP wafer ...
United States Steel Corporation (NYSE: X) (“U. S. Steel”) announced today that its Board of Directors declared a dividend of ...
Bitcoin for Corporations conference has kicked off day 2, featuring Wall Street executives and leading fintech professionals ...
Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the ...
PG&E Corporation recorded first-quarter 2024 income available for common shareholders of $732 million, or $0.34 per share, as ...
The American Bar Association (ABA) Business Law Section's Corporate Laws Committee has recently launched the Model Business ...
Q3 2024 Earnings Call Transcript May 1, 2024 Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, ...
Pembina Pipeline Corporation ("Pembina" or the "Company") (TSX ... Pursuant to the terms of the Series 5 Shares, as June 1, 2024, is not a business day, payment will occur on June 3, 2024. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback